Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
IPO Year: 1991
Exchange: NASDAQ
Website: alkermes.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $40.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | $21.00 → $38.00 | Sell → Neutral | UBS |
| 2/11/2025 | $40.00 | Buy | Deutsche Bank |
| 11/5/2024 | $25.00 → $36.00 | Hold → Buy | Stifel |
| 6/17/2024 | $34.00 | Buy | TD Cowen |
| 3/19/2024 | $37.00 | Outperform | Robert W. Baird |
| 2/20/2024 | $25.00 | Neutral → Sell | UBS |
| 11/20/2023 | $33.00 | Neutral | JP Morgan |
| 10/24/2023 | In-line → Outperform | Evercore ISI | |
| 10/17/2023 | $31.00 | Neutral | UBS |
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev
DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc is a global biopharmaceutic
DUBLIN, April 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioi
DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness. "The initiation of Vibrance-3 represents an important step forward for the ALKS 2680 development program as we seek to advance a potential new treatment option for people living with
DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual Health Care ConferenceDate/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET (2:50 p.m. GMT) Leerink Partners Global Healthcare Conference 2025Date/Time: Wednesday, March 12, 2025 at 11:20 a.m. ET (3:20 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of propri
— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN, Feb. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company.
DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the
DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for
DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx ConferenceDate/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT) Piper Sandler 36th Annual Healthcare ConferenceDate/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for th
DUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) Jefferies London Healthcare ConferenceDate/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol depen
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13D/A - Alkermes plc. (0001520262) (Subject)
SC 13D/A - Alkermes plc. (0001520262) (Subject)
SCHEDULE 13G - Alkermes plc. (0001520262) (Subject)
DEFA14A - Alkermes plc. (0001520262) (Filer)
10-Q - Alkermes plc. (0001520262) (Filer)
8-K - Alkermes plc. (0001520262) (Filer)
8-K - Alkermes plc. (0001520262) (Filer)
DEFA14A - Alkermes plc. (0001520262) (Filer)
DEF 14A - Alkermes plc. (0001520262) (Filer)
PRE 14A - Alkermes plc. (0001520262) (Filer)
144 - Alkermes plc. (0001520262) (Subject)
10-K - Alkermes plc. (0001520262) (Filer)
RBC Capital Mkts initiated coverage of Alkermes Plc with a rating of Sector Perform and set a new price target of $40.00
UBS upgraded Alkermes Plc from Sell to Neutral and set a new price target of $38.00 from $21.00 previously
Deutsche Bank initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $40.00
Stifel upgraded Alkermes Plc from Hold to Buy and set a new price target of $36.00 from $25.00 previously
TD Cowen initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $34.00
Robert W. Baird initiated coverage of Alkermes Plc with a rating of Outperform and set a new price target of $37.00
UBS downgraded Alkermes Plc from Neutral to Sell and set a new price target of $25.00
JP Morgan resumed coverage of Alkermes Plc with a rating of Neutral and set a new price target of $33.00
Evercore ISI upgraded Alkermes from In-line to Outperform
UBS initiated coverage of Alkermes with a rating of Neutral and set a new price target of $31.00
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev
DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc is a global biopharmaceutic
— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN, Feb. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company.
DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong year-over-year growth of our portfolio of proprietary commercial products and position us well to meet our strategic, operational and financial priorities for the year. Looking ahead, we believe growing our
DUBLIN, Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plcAlkermes plc is a global biopharmaceutical
— Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from Continuing Operations of $94.7 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.55 — — Company Reiterates 2024 Financial Expectations — DUBLIN, July 24, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2024. "Our second quarter results reflect solid execution across our business, delivering double-digit, year-over-year growth for our proprietary commercial product portfolio and robust profitability. We enter the second half of the year in a strong
DUBLIN, July 17, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 24, 2024 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plcAlkermes plc is a global biopharmaceutic
— First Quarter Revenues of $350.4 Million — — GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 — — Company Reiterates 2024 Financial Expectations — DUBLIN, May 1, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities across the business, highlighted by solid underlying prescription growth for LYBALVI® and advancement of ALKS 2680, our novel, investigational, oral orexin 2
DUBLIN, April 17, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc is a global biopharmaceutica
DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t
— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — — Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. "Dr. Loew's deep knowledge of the oncology fi
DUBLIN, May 8, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts. The preliminary proxy statement is available on the Investor Relations section of the company's website at www.alkermes.com. Independent Director Nomination Process As outlined in the company's preliminary proxy statement, the Nominating and Corporate Governance Committee of Alkermes' Board of Directors (the Board) re
– Appoints Nancy J. Wysenski as New Lead Independent Director – – David W. Anstice AO and Wendy L. Dixon, Ph.D. to Retire From Board – – Files Preliminary Proxy Statement and Highlights Shareholder Engagement Efforts – DUBLIN, May 26, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced a series of actions as part of its ongoing commitment to strong corporate governance and regular board refreshment. The company also filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The preliminary proxy statement is available on the Investor Relations section of
DUBLIN, Nov. 19, 2021 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company's Board of Directors. Dr. Laurencin is a distinguished university professor, award-winning engineer, orthopaedic surgeon, scientist, administrator, and pioneer in the field of regenerative engineering. Dr. Laurencin is actively involved in mentoring and social justice initiatives and has been widely recognized for his work promoting diversity and excellence in science and addressing health disparities. He currently serves as a professor of multiple disciplines at the University of Connecticut (UConn). He is the Universi
DUBLIN, May 20, 2021 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Emily Peterson Alva, to the company's Board of Directors ("Board"). Emily Peterson Alva is an experienced public company board member and a financial, strategic and business advisor to growth companies. A former Lazard M&A Partner with more than 15 years of investment banking experience, Ms. Alva brings significant experience navigating complex strategic, transactional and governance matters for public companies across many sectors including specific expertise in healthcare and pharmaceuticals. "I am delighted to welcome Emily to Alkermes' Board of Directors and look
DUBLIN, Dec. 10, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial performance and enhance shareholder value, as the company continues to advance its mission of developing new medicines designed to have a real-world impact in the treatment of serious mental illness, addiction and cancer. The Plan includes a commitment to multi-year profitability targets, a review and optimization of the company's cost structure, potential monetization of non-core assets, and continued governance enhancements, including the addition of two new independent directors with substantial financial an